Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by NeuroSigma, Inc.

News headline image
NeuroSigma Expands Payment Options for the Monarch eTNS® System
From NeuroSigma, Inc.
Via GlobeNewswire
News headline image
NeuroSigma Announces U.S. Commercial Launch of Second-Generation Monarch® eTNS System for Pediatric ADHD
From NeuroSigma, Inc.
Via GlobeNewswire
News headline image
NeuroSigma Completes $1 Million Investment into High-Volume Manufacturing Line for Second Generation Monarch eTNS® Device
From NeuroSigma, Inc.
Via GlobeNewswire
News headline image
NeuroSigma Launches Next-Generation Monarch Device for Pediatric ADHD After Successful Pilot Program
From NeuroSigma, Inc.
Via GlobeNewswire
News headline image
NeuroSigma Announces New Publication Showing Real-Time Effects of External Trigeminal Nerve Stimulation (eTNS) on Brain Activity
From NeuroSigma, Inc.
Via GlobeNewswire
News headline image
NeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China
From NeuroSigma, Inc.
Via GlobeNewswire
News headline image
NeuroSigma Announces New Clinical Trial of Monarch eTNS System for Treatment of ADHD in Children with Fetal Alcohol Syndrome at UCLA
From NeuroSigma, Inc.
Via GlobeNewswire
News headline image
NeuroSigma Announces Patent Application Protecting Use of Trigeminal Nerve Stimulation to Include Treatment of Dyslexia and Other Neurodevelopmental Disorders
From NeuroSigma, Inc.
Via GlobeNewswire
News headline image
Clinical Trial of NeuroSigma’s Monarch eTNS System for ADHD at King’s College London Completes Enrollment
From NeuroSigma, Inc.
Via GlobeNewswire
News headline image
New Clinical Trial of eTNS for Pediatric ADHD to Commence at Denmark’s Center for Evidence-Based Psychiatry
From NeuroSigma, Inc.
Via GlobeNewswire
News headline image
NeuroSigma Announces Acceptance into 2024 Cohort of the KidsX Accelerator Program
From NeuroSigma, Inc.
Via GlobeNewswire
News headline image
NeuroSigma Announces FDA Clearance of its Second-Generation Monarch eTNS System for Treating Pediatric ADHD
From NeuroSigma, Inc.
Via GlobeNewswire
News headline image
NeuroSigma Announces FDA 510(k) Submission for Second Generation Monarch eTNS System
From NeuroSigma, Inc.
Via GlobeNewswire
News headline image
NeuroSigma Announces HSA Approval of the Monarch eTNS System in Singapore
From NeuroSigma, Inc.
Via GlobeNewswire
News headline image
NeuroSigma Establishes Singapore Subsidiary
From NeuroSigma, Inc.
Via GlobeNewswire
News headline image
NeuroSigma Announces New Telehealth Option for Patients and Caregivers Interested in eTNS for Pediatric ADHD
From NeuroSigma, Inc.
Via GlobeNewswire
News headline image
NeuroSigma Announces Strategic Digital Marketing Partnership with Data360
From NeuroSigma, Inc.
Via GlobeNewswire
News headline image
NeuroSigma Announces that Enrollment Commences in Two Large, Double-Blind Trials of eTNS for Pediatric ADHD
From NeuroSigma, Inc.
Via GlobeNewswire
News headline image
NeuroSigma Announces Commercial Launch of The Monarch eTNS® System for the Treatment of Pediatric ADHD at Annual Meeting of the American Academy of Child and Adolescent Psychiatry
From NeuroSigma, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.